Centessa Pharmaceuticals (CNTA) Morgan Stanley 23rd Annual Global Healthcare Conference summary

Program progress and scientific insights

• Significant advancements in the orexin agonist program, with ORX750 and ORX142 showing promise for treating narcolepsy and related disorders.

• Orexin agonists target the underlying cause of narcolepsy type 1 by restoring orexin signaling, potentially transforming patient outcomes.

• Phase I data for ORX750 demonstrated the ability to maintain wakefulness and normalize sleepiness scores in healthy volunteers.

• ORX142, a next-generation molecule, is more potent and may allow lower dosing and broader application, including neurodegenerative and neuropsychiatric indications.

• Real-time adaptive clinical trial design enables flexible dose optimization across NT1, NT2, and IH populations.

Competitive landscape and differentiation

• ORX750 is designed for once-daily or split dosing, with a proprietary structure enabling strong differentiation from other orexin-2 agonists.

• The molecule's PK/PD profile and medicinal chemistry innovations provide dosing flexibility and potential best-in-class status.

• Competitor data reinforces the commercial focus and ambition to dominate the rare hypersomnia market.

• Having one molecule for all three indications simplifies treatment for physicians and maximizes market reach.

• Intellectual property position is strong due to the limited chemical space of the orexin-2 receptor binding pocket.

Market opportunity and physician feedback

• The rare hypersomnia market is estimated at over $15 billion, with NT1 alone valued at $6–7 billion.

• Physician and key opinion leader feedback indicates high enthusiasm and anticipation for orexin agonists, with expectations for a shift toward monotherapy.

• The class is expected to redefine the standard of care, potentially reducing the need for polypharmacy.

• Uptake post-launch is expected to be strong due to the significant unmet need and transformative efficacy.

• Next-generation molecules may further expand the addressable market beyond rare hypersomnias.